Dolutegravir Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 10 mg, 25 mg, 50 mg
Reference Brands: Tivicay(Us & EU)
Category:
Anti Viral
Dolutegravir is an HIV-1 treatment from the integrase inhibitor class that blocks viral replication. Approved by the US FDA and EMA, it is used alone or in combination therapies like Tivicay, Triumeq, and Dovato. Known for strong efficacy and once-daily dosing.
Dolutegravir is available in Tablet
and strengths such as 10 mg, 25 mg, 50 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Dolutegravir is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Dolutegravir can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Dolutegravir is a potent antiretroviral drug used for the treatment of HIV-1 infection. As an integrase strand transfer inhibitor (INSTI), it blocks the enzyme HIV integrase, preventing viral replication. Dolutegravir is available as a standalone medication (brand name Tivicay) and in fixed-dose combinations like Triumeq, Dovato, and Juluca. Approved by the US FDA and EMA, it is used in both adults and children. Known for its once-daily dosing, high genetic barrier to resistance, and strong efficacy, Dolutegravir is a preferred first-line HIV therapy recommended by WHO and leading HIV treatment guidelines globally. Ideal for long-term HIV management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing